Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jazz PharmaceuticalsFRA:J7Z +0.54%73 PB Ratio is 3.58 as of Jul. 25, 2026, which is 39% above its 10-year median of 2.58. GuruFocus rates FRA:J7Z with a GF Score™ of 73/100 and a GF Value™ of €132.71 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,229 Biotechnology companies, Jazz Pharmaceuticals ranks worse than 59.15% on this metric.
Jazz Pharmaceuticals PLC stock PB Ratio (=3.51) is close to 5-year high of 3.65.
The historical rank and industry rank for Jazz Pharmaceuticals's PB Ratio or its related term are showing as below:
FRA:J7Z'
s PB Ratio Range Over the Past 10 Years
Min: 1.44 Med: 2.58 Max: 5.4
Current: 3.51
During the past 13 years, Jazz Pharmaceuticals's highest PB Ratio was 5.40. The lowest was 1.44. And the median was 2.58.
FRA:J7Z's PB Ratio is ranked worse than 59.15% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs FRA:J7Z: 3.51
During the past 12 months, Jazz Pharmaceuticals's average Book Value Per Share Growth Rate was 6.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Jazz Pharmaceuticals was 208.20% per year. The lowest was -30.00% per year. And the median was 12.75% per year.
Back to Basics: PB Ratio
Jazz Pharmaceuticals (FRA:J7Z) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Jazz Pharmaceuticals PB Ratio Related Terms
Jazz Pharmaceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jazz Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jazz Pharmaceuticals (FRA:J7Z) has a PB Ratio of 3.58 as of Jul. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jazz Pharmaceuticals and its competitors. This is 39% above median its historical median of 2.58. Over the past decade, Jazz Pharmaceuticals' PB Ratio has ranged from 1.44 to 5.40. According to the industry distribution chart, Jazz Pharmaceuticals ranks #727 out of 1229 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Jazz Pharmaceuticals' PB Ratio too high?
Jazz Pharmaceuticals' current PB Ratio of 3.58 is 39% above median its 10-year median of 2.58. Over the past 10 years, this metric has ranged from a low of 1.44 to a high of 5.40. The Biotechnology industry median PB Ratio is 2.79. Jazz Pharmaceuticals' value of 3.58 is 28.3% above this industry median. Based on the distribution chart, Jazz Pharmaceuticals ranks #727 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' PB Ratio compare to BBIO and EXEL?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #727 out of 1229 companies for PB Ratio. This places Jazz Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.79. Jazz Pharmaceuticals' value of 3.58 is 28.3% above this benchmark. Historically, Jazz Pharmaceuticals' own PB Ratio has ranged from 1.44 to 5.40 over the past decade. While the company's 10-year median is 2.58 vs. the industry median of 2.79, Jazz Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jazz Pharmaceuticals's current PB Ratio of 3.58 is 28.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jazz Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jazz Pharmaceuticals's current PB Ratio is 3.58, which is 39% above median its own 10-year median of 2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €132.71, compared to a current price of €224.00 — trading 68.8% above its estimated fair value. The current PB Ratio is 3.58, which is 39% above median its 10-year median of 2.58 and 28.3% above the Biotechnology industry median of 2.79. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current PB Ratio is 3.58 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of €224.00 is trading 68.8% above its estimated GF Value™ of €132.71.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:J7Z:
PB Ratio: 3.58 (39% above median its 10-year median of 2.58)
GF Value™: €132.71 vs. price of €224.00 (68.8% above fair value)
Industry Position: 28.3% above the Biotechnology median (#727 of 1229)
No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for FRA:J7Z
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J7Z has been successfully added to your 
